- Home
- CUE vs BCV Comparison
CUE vs BCV Comparison
Compare CUE & BCV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CUE | BCV |
|---|---|---|
| Founded | 2014 | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 124.5M | 128.4M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | CUE | BCV |
|---|---|---|
| Price | $27.00 | $24.52 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $120.00 | N/A |
| AVG Volume (30 Days) | ★ 160.0K | 16.8K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.13% |
| EPS Growth | ★ 61.11 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $27,466,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 195.75 | N/A |
| 52 Week Low | $0.17 | $19.69 |
| 52 Week High | $45.50 | $27.33 |
Technical Indicators
Market Signals| Indicator | CUE | BCV |
|---|---|---|
| Relative Strength Index (RSI) | 44.09 | 47.25 |
| Support Level | $24.49 | $23.93 |
| Resistance Level | $33.73 | $24.49 |
| Average True Range (ATR) | 3.15 | 0.49 |
| MACD | -0.78 | 0.08 |
| Stochastic Oscillator | 16.97 | 64.10 |
Price Performance
Historical ComparisonAbout CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About BCV Bancroft Fund Ltd.
Bancroft Fund Ltd is a diversified closed-end management company. It operates as a closed-ended equity mutual fund. The funds' main objective is to provide income and potential for capital appreciation. With the intent to achieve its objective, the company invests in convertible and equity securities. It invests across different industries such as Computer Software and Services, Energy and Utilities, Health Care among others.